ERBB2 and breast carcinoma: The International Ki67 in Breast Cancer Working Group has recently concluded that Ki67, a proliferation biomarker, is also a prognostic marker for BC, but its clinical value is limited to ER+/HER2− patients, serving to stratify the cases from this group, which will benefit from adjuvant chemotherapy34.